West Pharmaceutical Services (WST) Q1 2025 earnings summary

Executive summary

• Q1 2025 net sales were $698 million, up 0.4% year-over-year, with organic growth of 2.1%; adjusted EPS was $1.45, both exceeding guidance, driven by strong GLP-1 and self-injection device demand.

• Net income was $89.8 million, down from $115.3 million in Q1 2024, mainly due to higher restructuring charges and a higher effective tax rate.

• Leadership changes included the announced departure of CFO Bernard Birkett and the appointment of Shane Campbell as SVP, Chief Proprietary Segment Officer.

• The company implemented a restructuring plan in January 2025, incurring $17.8 million in related charges in Q1.

• Board declared a Q3 2025 dividend of $0.21 per share, payable August 6, 2025.

Financial highlights

• Gross profit was $231.9 million, up 0.7% year-over-year; gross margin rose to 33.2%.

• Adjusted operating profit for Q1 2025 was $125.0 million (17.9% margin), compared to $123.0 million (17.7%) last year.

• Operating cash flow for Q1 was $129.4 million, up 9.5% year-over-year; free cash flow increased to $58.1 million from $27.6 million.

• Capital expenditures were $71.3 million, down from $90.6 million year-over-year.

• 550,281 shares repurchased for $133.5 million at an average price of $242.63.

Outlook and guidance

• Full-year 2025 net sales guidance raised to $2.945–$2.975 billion, up from $2.875–$2.905 billion.

• Adjusted diluted EPS guidance increased to $6.15–$6.35, up from $6.00–$6.20, including $20–$25 million in tariff costs.

• Organic net sales growth expected at 2–3% for 2025; capital spending guidance unchanged at $275 million.

• Q2 2025 revenue expected at $720–$730 million, with 3–4% organic sales growth; adjusted EPS $1.50–$1.55.

• Guidance assumes a 22% tax rate for the remainder of 2025 and no further stock-based compensation tax benefits.